Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

Mehra, Siddharth; Garrido, Vanessa T.; Dosch, Austin R.; Lamichhane, Purushottam; Srinivasan, Supriya; Singh, Samara P.; Zhou, Zhiqun; De Castro Silva, Iago; Joshi, Chandrashekar; Ban, Yuguang; Datta, Jashodeep; Gilboa, Eli; Merchant, Nipun B.; Nagathihalli, Nagaraj S.

doi:10.1158/2767-9764.23668690.v1

Figure S4 from Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

https://doi.org/10.1158/2767-9764.23668690

journal contribution

posted on 2023-07-12, 14:20 authored by Siddharth Mehra, Vanessa T. Garrido, Austin R. Dosch, Purushottam Lamichhane, Supriya Srinivasan, Samara P. Singh, Zhiqun Zhou, Iago De Castro Silva, Chandrashekar Joshi, Yuguang Ban, Jashodeep Datta, Eli Gilboa, Nipun B. Merchant, Nagaraj S. Nagathihalli

<p>Tumor weight, mouse weight and cytokine profiling of Uro A treatment in PKT mice.</p>

Funding

HHS | NIH | National Cancer Institute (NCI)

Florida Department of Health

American Cancer Society (ACS)

History

Related Materials

1.
DOI - Is supplement to Remodeling of Stromal Immune Microenvironment by Urolithin A Improves Survival with Immune Checkpoint Blockade in Pancreatic Cancer

ARTICLE ABSTRACT

Immunotherapeutic agents are ineffective against pancreatic cancer, mainly due to the immunosuppressive tumor microenvironment and stromal desmoplasia. Our current study demonstrates the therapeutic utility of a novel gut microbial metabolite, Uro A, to remodel the stromal-immune microenvironment and improve overall survival with anti-PD-1 therapy in pancreatic cancer.